Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Oct;98(2):451–454. doi: 10.1111/j.1476-5381.1989.tb12617.x

Lorazepam discontinuation promotes 'inverse agonist' effects of benzodiazepines.

A Schatzki 1, F Lopez 1, D J Greenblatt 1, R I Shader 1, L G Miller 1
PMCID: PMC1854718  PMID: 2573401

Abstract

1. The effects of lorazepam discontinuation on responses to benzodiazepine agonists and antagonists were studied in mice. 2. The convulsant dose of pentylenetetrazol was decreased after an acute dose of lorazepam (0.5 mg kg-1) at 4 days after drug discontinuation, compared to 1 or 7 days after discontinuation or to vehicle treatment. 3. The percentage of mice undergoing convulsions after an acute dose of FG 7142 (40 mg kg-1) was increased at 4 days after lorazepam discontinuation, compared to 1 or 7 days after discontinuation or to vehicle treatment. 4. After an acute dose (0.5 mg kg-1), lorazepam concentrations in cortex tended to be greater in lorazepam-treated compared to vehicle-treated mice at 4 days after discontinuation compared to 1 and 7 days. 5. These data indicate a shift toward reduced agonist sensitivity and increased inverse agonist sensitivity in mice 4 days after lorazepam discontinuation.

Full text

PDF
451

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Crawley J. N., Marangos P. J., Stivers J., Goodwin F. K. Chronic clonazepam administration induces benzodiazepine receptor subsensitivity. Neuropharmacology. 1982 Jan;21(1):85–89. doi: 10.1016/0028-3908(82)90216-7. [DOI] [PubMed] [Google Scholar]
  2. File S. E. Recovery from lorazepam tolerance and the effects of a benzodiazepine antagonist (RO 15-1788) on the development of tolerance. Psychopharmacology (Berl) 1982;77(3):284–288. doi: 10.1007/BF00464581. [DOI] [PubMed] [Google Scholar]
  3. Greenblatt D. J., Franke K., Shader R. I. Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam. J Chromatogr. 1978 Sep 1;146(2):311–320. [PubMed] [Google Scholar]
  4. Greenblatt D. J., Shader R. I., Abernethy D. R. Drug therapy. Current status of benzodiazepines. N Engl J Med. 1983 Aug 18;309(7):410–416. doi: 10.1056/NEJM198308183090705. [DOI] [PubMed] [Google Scholar]
  5. Greenblatt D. J., Shader R. I. Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev. 1978;8(1):13–28. doi: 10.3109/03602537808993775. [DOI] [PubMed] [Google Scholar]
  6. Little H. J., Nutt D. J., Taylor S. C. Bidirectional effects of chronic treatment with agonists and inverse agonists at the benzodiazepine receptor. Brain Res Bull. 1987 Sep;19(3):371–378. doi: 10.1016/0361-9230(87)90106-7. [DOI] [PubMed] [Google Scholar]
  7. Medina J. H., de Stein M. L., De Robertis E. n-[3H]butyl-beta-carboline-3-carboxylate, a putative endogenous ligand, binds preferentially to subtype 1 of central benzodiazepine receptors. J Neurochem. 1989 Mar;52(3):665–670. doi: 10.1111/j.1471-4159.1989.tb02506.x. [DOI] [PubMed] [Google Scholar]
  8. Miller L. G. Effects of chronic drug use: defining our terms. J Clin Psychopharmacol. 1988 Oct;8(5):309–310. [PubMed] [Google Scholar]
  9. Miller L. G., Greenblatt D. J., Abernethy D. R., Friedman H., Luu M. D., Paul S. M., Shader R. I. Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites. Psychopharmacology (Berl) 1988;94(3):386–391. doi: 10.1007/BF00174694. [DOI] [PubMed] [Google Scholar]
  10. Miller L. G., Greenblatt D. J., Barnhill J. G., Shader R. I. Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acidA receptor function. J Pharmacol Exp Ther. 1988 Jul;246(1):170–176. [PubMed] [Google Scholar]
  11. Miller L. G., Greenblatt D. J., Roy R. B., Summer W. R., Shader R. I. Chronic benzodiazepine administration. II. Discontinuation syndrome is associated with upregulation of gamma-aminobutyric acidA receptor complex binding and function. J Pharmacol Exp Ther. 1988 Jul;246(1):177–182. [PubMed] [Google Scholar]
  12. Nutt D. J., Taylor S. C., Little H. J. Optimizing the pentetrazol infusion test for seizure threshold measurement. J Pharm Pharmacol. 1986 Sep;38(9):697–698. doi: 10.1111/j.2042-7158.1986.tb03114.x. [DOI] [PubMed] [Google Scholar]
  13. Nutt D. J., Taylor S. C., Little H. J., Standing B. L., Gale R. G. Changes in benzodiazepine/GABA receptor complex function in benzodiazepine-tolerant mice. Psychopharmacology (Berl) 1988;95(3):407–412. doi: 10.1007/BF00181957. [DOI] [PubMed] [Google Scholar]
  14. Owen R. T., Tyrer P. Benzodiazepine dependence. A review of the evidence. Drugs. 1983 Apr;25(4):385–398. doi: 10.2165/00003495-198325040-00003. [DOI] [PubMed] [Google Scholar]
  15. Petursson H., Lader M. H. Benzodiazepine dependence. Br J Addict. 1981;76(2):133–145. doi: 10.1111/j.1360-0443.1981.tb00218.x. [DOI] [PubMed] [Google Scholar]
  16. Roy-Byrne P. P., Hommer D. Benzodiazepine withdrawal: overview and implications for the treatment of anxiety. Am J Med. 1988 Jun;84(6):1041–1052. doi: 10.1016/0002-9343(88)90309-9. [DOI] [PubMed] [Google Scholar]
  17. Scharf M. B., Feil P. Acute effects of drug administration and withdrawal on the benzodiazepine receptor. Life Sci. 1983 Apr 11;32(15):1771–1777. doi: 10.1016/0024-3205(83)90841-x. [DOI] [PubMed] [Google Scholar]
  18. Woods J. H., Katz J. L., Winger G. Abuse liability of benzodiazepines. Pharmacol Rev. 1987 Dec;39(4):251–413. [PubMed] [Google Scholar]
  19. Woods J. H., Katz J. L., Winger G. Use and abuse of benzodiazepines. Issues relevant to prescribing. JAMA. 1988 Dec 16;260(23):3476–3480. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES